ZENEO® Apomorphine : Salvage treatment for temporary paralysis in Parkinson's disease.
Apomorphine is used to treat temporary paralysis, also known as off episodes, in Parkinson's disease.
This latter affects 700,000 people in Europe, 1.2 million in the United States, and 6.3 million worldwide (1).
It is the second most-frequent neurodegenerative disorder after Alzheimer's disease.
With the world's population aging, the number of patients with Parkinson's disease is expected to double over the next thirty years.
The disease's chronic effects are due to the progressive breakdown of certain nerve cells in the brain.
The efficacy of the most frequently used treatments diminishes over time. When that occurs, patients may start experiencing "off episodes", that is, a period when the symptoms of difficult or impossible ("freezing") movement return.
Apomorphine is the reference salvage medication for these episodes.
ZENEO® Apomorphine acts on the brain's nerve cells within five to ten minutes to free the patient from the temporary paralysis. It represents a novel source of comfort and a renewed social life for patients and their loved-ones.
(1) Epda : www.epda.eu.com
When experiencing a temporary paralysis in Parkinson's disease, the patient can self-administer ZENEO® Apomorphine in the thigh.
Another person could also administer the product for the patient, in a ventrogluteal injection.